Perspectives of renal denervation from hypertension to heart failure in Asia

Abstract

Hypertension is the most powerful risk factor of cardiovascular disease [1], and antihypertensive treatment significantly reduces the rate of atherosclerotic cardiovascular events and heart failure in patients with hypertension [2–4]. There are evidence of experiment studies which support the renal denervation (RDN) is effective to reduce sympathetic activity and blood pressure (BP) [5]. Recently, evidence from several sham-controlled clinical trials of RDN in patients with hypertension with and without medication has been published [6–8]. The majority of these trials showed a significant reduction in BP after RDN, regardless of the device used. In this issue of Hypertension Research, longterm follow-up results from a real-world registry, Global SYMPLICITY Registry (GSR) Korea, have been published [9]. In addition, the meta-analysis and systematic review of recent sham-controlled clinical trials [10], including REQUIRE [11] and RADIANCE Trio [12] and the result of patient preference survey in Japan [13] have been released in this issue. Here, we discuss the clinical implication and perspectives of a RDN-based hypertension management strategy in Asia.